SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCJuly 14, 2026

ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities

Antibody-drug conjugates have moved quickly from a promising idea to a fixture of cancer treatment, and a group of specialists convened by the ETOP IBCSG Partners Foundation has now set out where the field should concentrate next. Writing in ESMO Open, the authors summarise the conclusions of the foundation's third expert workshop, which brought together clinicians across several solid tumours, laboratory scientists and pharmaceutical industry representatives to weigh the evidence and agree research priorities. Their central point is that these drugs are no longer experimental in many settings, and that the open questions now are about how to use them well: which patients, in which order, and guided by which biomarkers. The group was led by Solange Peters and Rolf A. Stahel, both Lung Summit faculty.
Share

In brief

  • Antibody-drug conjugates have become part of standard treatment across several solid tumours, so the open questions now are less about whether they work and more about how best to use them.
  • The group argues that research priorities should be set separately for each tumour type, starting with the settings where an antibody-drug conjugate could take the place of chemotherapy.
  • It calls for more caution before a drug jumps from early-phase studies into large phase III trials, with prespecified evidence thresholds met first.
  • Validating predictive biomarkers, potentially with help from artificial intelligence, is flagged as the field’s next major task.

Read the full paper in ESMO Open →

What the workshop set out to do

The European Thoracic Oncology Platform and the International Breast Cancer Study Group established the ETOP IBCSG Partners Foundation workshops as a recurring forum to review the evidence on antibody-drug conjugates and to offer recommendations for future research. This paper reports the third meeting in that series. The authors describe a deliberately cross-disciplinary group, spanning several tumour types alongside basic and translational scientists and pharmaceutical industry representatives, assembled so that lessons learned in one cancer can inform work in others.

That cross-tumour framing runs through the whole statement. Because an antibody-drug conjugate couples an antibody to a cytotoxic payload, experience with a given target or payload in one disease often carries over to another, and the authors treat the field as a single body of knowledge rather than a set of separate stories in lung, breast or bladder cancer.

Where antibody-drug conjugates now stand

The position statement notes that recent positive phase III results have written several antibody-drug conjugates into standard care across a range of cancers. In lung cancer the authors cite sacituzumab tirumotecan; in breast cancer, trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan; in muscle-invasive bladder cancer, enfortumab vedotin; in ovarian cancer, mirvetuximab soravtansine; and in cervical cancer, tisotumab vedotin. It is a broad footprint for a class of drugs that only recently was confined to later lines of treatment.

Because the drugs have advanced at different rates in different diseases, the group argues that research priorities have to be set tumour by tumour rather than for the class as a whole. The first place to look, in their view, is the set of situations where an antibody-drug conjugate could replace chemotherapy outright, since that is where the potential gain for patients is largest and the comparison with existing treatment is clearest.

A note of caution on trial design

The authors also question how quickly some of these drugs have moved into large trials. Many phase III studies, they observe, have been launched on the strength of positive phase I data. While the resulting trials are larger than those run historically, the group recommends that prespecified thresholds, such as the number of patients treated and the magnitude of efficacy seen in the earlier study, should be met before a programme proceeds directly to phase III. The aim is to avoid committing large numbers of patients to expensive confirmatory trials on evidence that has not yet cleared an agreed bar.

Biomarkers as the next priority

Much of the statement turns on biomarkers. The authors acknowledge that several antibody-drug conjugates have been developed successfully without a mandatory biomarker for patient selection, but they argue that a biomarker-driven approach lets treatment be directed more rationally.

“Importantly, although several ADCs have been successfully developed without mandatory biomarker selection, biomarker-driven ADC development enables rational patient selection, as illustrated by multiple ADCs (e.g. T-DXd, mirvetuximab soravtansine and telisotuzumab vedotin).”Peters et al., ESMO Open (2026)

Developing and validating such predictive biomarkers will not be straightforward, the authors caution. They point to several complications that can affect a biomarker reading, including the algorithm used to score it and the type of specimen analysed, both of which may be distorted by differences in a tumour over time and between sites. Alongside this, the group lists two further continuing priorities: optimising the conjugates themselves, to improve the balance between efficacy and tolerability, and the search for reliable molecular targets that mark out the patients most likely to benefit.

Bringing artificial intelligence to bear

Given the volume of data now being generated on these drugs, the authors suggest that artificial intelligence could be used to analyse combined datasets and to build composite biomarkers, drawing together tumour histology, target expression thresholds, molecular alterations and the pathways that affect how a drug’s payload behaves. Used in that way, they propose, such analysis could help turn the workshop’s research agenda into a set of testable questions rather than a wish list.

Sources

  1. ESMO Open. Antibody-drug conjugates across solid tumours: an ETOP/IBCSG expert group sets the research priorities (2026-07-10). esmoopen.com

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Rolf A. Stahel, Solange Peters, Giannis Mountzios, Antonio Passaro, Noemí Reguart and Jordi Remon.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf